No longer a mere assistant who carries out the commands of DNA, RNA takes the lead in emerging therapeutics.

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA ...

Professor Hirohide Saito (Department of Life Science Frontiers at CiRA / The University of Tokyo) and Assistant Professor ...

Global Antisense and RNAi therapeutics Market is valued approximately at USD 3.69 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 18.72% over the forecast period ...

Discover how unique circular RNA molecules are transforming liver cancer research to combat this growing health concern.

If the pre-mRNA is defective, GPATCH1 recognizes that the spliceosome should discontinue its work. As a second factor, DHX35 strips away the unsuitable precursor mRNA and eliminates it. Afterwards, ...

Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger ...

Conclusion: Our study employed a minigene system, which offers great flexibility for assessing aberrant splicing patterns when patient mRNA samples are not accessible, to investigate the effects of ...

RNA splicing, a process discovered in the late 1970s, allows cells to precisely control the content of the mRNA transcripts that carry the instructions for building proteins.

Late-onset Alzheimer's disease is a debilitating, progressive neurodegenerative disease that affects about 7 million Americans, a figure that is expected to nearly double by 2050, according to the ...

The new partners aim to develop new splice modulators for multiple disease areas, including oncology, with Rgenta able to receive up to nearly $500 million biobucks per target.